Aytu Biopharma (AYTU) 2nd Annual Lytham Partners Healthcare Investor Summit summary

Exxua launch and differentiation

• Exxua was acquired through a partnership with Fabre-Kramer Pharmaceuticals after initial contact at the JPMorgan Healthcare Conference, aligning with existing psychiatry-focused infrastructure.

• Exxua is the first and only 5-HT1A agonist for major depressive disorder, offering a unique mechanism distinct from SSRIs and SNRIs, with fewer sexual and weight gain side effects.

• The product is positioned for initial use as a later-line therapy, with potential to move earlier as prescriber familiarity and payer access improve.

• Sales force and commercial infrastructure were rapidly realigned to focus exclusively on high-prescribing psychiatrists for depression.

• Messaging to prescribers emphasizes Exxua’s novel mechanism, rapid onset, favorable side effect profile, and ease of patient access.

Commercial strategy and RxConnect

• The RxConnect platform streamlines access, offering predictable copays and minimizing prior authorization hurdles, which has proven effective in the ADHD market.

• RxConnect partners with a network of pharmacies and select retail chains, enabling seamless prescription fulfillment and high patient adherence.

• The program benefits all stakeholders: patients, physicians, pharmacies, and the company, resulting in sticky business and improved uptake.

• Early feedback indicates strong physician interest, especially among those already familiar with RxConnect.

Legacy business performance and generic competition

• The ADHD franchise, including Adzenis and Cotempla, generated $55.5 million in the trailing 12 months, with pediatric products contributing an additional $8–8.5 million.

• The business has remained stable but faces ongoing risk from generic intrusion, particularly from Teva, which recently launched a competing product.

• An authorized generic for Adzenis was launched internally, capturing significant market share and mitigating the impact of external generics.

• The RxConnect network processes about 85% of ADHD prescriptions, making it difficult for competitors to penetrate the core business.